INS018_073: AI identifies a preclinical candidate for renal fibrosis
Insilico Medicine named INS018_073 a preclinical candidate after in vitro tests and testing in a mouse model of renal fibrosis. The company reports improvements in pathology, biomarkers, and histologically observed fibrosis. The candidate was proposed for IND-enabling studies; these are company-reported preclinical results, not clinical evidence or independent confirmation.
Technology: Pharma.AI / Chemistry42
Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Announcement only
- Test type: direct test
- Tested: Company-reported in vitro potency (nanomolar) and a mouse unilateral ureteral obstruction model with histology, plus a 14-day mouse safety study.
- Still unknown: No effect sizes, doses or biomarkers are named, and no independent confirmation or peer review is stated.
- AI role: AI-driven target and compound identification (PandaOmics) produced the candidate.
Evidence sources: https://insilico.com/blog/pcc_kidney
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.